Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. The Company is focused on delivering important new therapies to the millions of patients living with chronic skin conditions. Its goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. The Company's portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.

Type
Public
HQ
Menlo Park, US
Founded
2011
Size (employees)
95 (est)
Dermira was founded in 2011 and is headquartered in Menlo Park, US
Report incorrect company information

Key People/Management at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Kin Chan

Kin Chan

Vice President of Engineering
Janice Drew

Janice Drew

Vice President & Project Management
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy
Hans Hofland

Hans Hofland

VP of Research

Dermira Office Locations

Dermira has an office in Menlo Park
Menlo Park, US (HQ)
275 Middlefield Rd
Show all (1)
Report incorrect company information

Dermira Financials and Metrics

Dermira Financials

Dermira's revenue was reported to be $22.47 m in FY, 2016 which is a 207.8% increase from the previous period.
USD

Net income (Q2, 2017)

(38.6 m)

EBIT (Q2, 2017)

(38.5 m)

Market capitalization (20-Apr-2018)

361.3 m

Cash (30-Jun-2017)

418.3 m
Dermira's current market capitalization is $361.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

7.3 m22.5 m

Revenue growth, %

208%

General and administrative expense

3 m5 m9.5 m

R&D expense

11 m24.4 m20.9 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

1.7 m4.1 m3.8 m4.7 m5.9 m6.4 m8.3 m11.3 m13.6 m

R&D expense

6 m10.1 m13.5 m18.9 m22.9 m21.7 m17.8 m19.9 m26 m

Operating expense total

7.7 m14.2 m17.3 m23.6 m28.8 m28 m26.1 m31.2 m39.6 m

EBIT

(7.7 m)(14.2 m)(17.3 m)(16.3 m)(28.8 m)(28 m)(25.9 m)(30.1 m)(38.5 m)
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

55.4 m107.2 m41.8 m

Accounts Receivable

18.8 m

Inventories

1 m2.5 m10.6 m

Current Assets

105.5 m217.2 m284 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

50.8 m52.1 m32.7 m120.3 m92.4 m211 m55.7 m201.9 m418.3 m

Current Assets

51.4 m124.5 m122.5 m224.2 m193.2 m303.3 m273.5 m433.3 m698.7 m

PP&E

79 k177 k223 k284 k460 k435 k413 k1.1 m1 m

Goodwill

771 k771 k771 k771 k771 k771 k771 k771 k771 k
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(31.9 m)(78.4 m)(7.4 m)

Depreciation and Amortization

47 k72 k123 k

Inventories

(572 k)(1.2 m)(6.8 m)

Accounts Payable

3.2 m3.6 m4.3 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.8 m)(14 m)(17.2 m)(16.1 m)(28.4 m)(27.8 m)(25.5 m)(29.5 m)

Accounts Payable

3.2 m6.8 m5.6 m6.8 m12.5 m8.8 m6.2 m5.4 m
USDY, 2017

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Dermira News and Updates

Acne Vulgaris Treatment Market Analysis 2018-2025: Dermira Inc, ELORAC Inc, Galderma SA, Novan Inc, Novartis AG, Pfizer Inc

The recent research on the Acne Vulgaris Treatment market identifies the performance of the Acne Vulgaris Treatment industry by consumables, application, end-users and geography for the forecast period, 2018 to 2025. The Acne Vulgaris Treatment industry report uncovers the revenue the market will ge…
Report incorrect company information